4
MARKET OVERVIEW
Covers the key developments, trend analysis, and actionable insights to support strategic planning and positioning.
4.3
UNMET NEEDS AND WHITE SPACES
4.4
INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
4.5
STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5
INDUSTRY TRENDS
Maps the market evolution with focus on trend catalysts, risk factors, and growth opportunities across segments.
5.1
PORTER’S FIVE FORCES ANALYSIS
5.2
MACROECONOMIC OUTLOOK
5.2.2
GDP TRENDS AND FORECAST
5.2.3
TRENDS IN DIABETES CARE INDUSTRY
5.2.4
TRENDS IN INSULIN DELIVERY SYSTEMS INDUSTRY
5.3
SUPPLY CHAIN ANALYSIS
5.6.1
AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT (2022-2025)
5.6.2
AVERAGE SELLING PRICE TREND, BY COUNTRY (2022-2025)
5.8
KEY CONFERENCES AND EVENTS, 2025–2026
5.9
TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.10
INVESTMENT AND FUNDING SCENARIO
5.12
IMPACT OF 2025 US TARIFF – ASIA PACIFIC BLOOD GLUCOSE MONITORING DEVICES MARKET
5.12.3
PRICE IMPACT ANALYSIS
5.12.5
IMPACT ON END-USE INDUSTRIES
6
TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
6.1
KEY EMERGING TECHNOLOGIES
6.2
COMPLEMENTARY TECHNOLOGIES
6.3
TECHNOLOGY/PRODUCT ROADMAP
6.6
IMPACT OF AI/GEN AI ON ASIA PACIFIC BLOOD GLUCOSE MONITORING DEVICES MARKET
6.6.1
TOP USE CASES AND MARKET POTENTIAL
6.6.2
BEST PRACTICES IN DIABETES CARE MANAGEMENT
6.6.3
CASE STUDIES OF AI IMPLEMENTATION IN ASIA PACIFIC BLOOD GLUCOSE MONITORING DEVICES MARKET
6.6.4
INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS
6.6.5
CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN ASIA PACIFIC BLOOD GLUCOSE MONITORING DEVICES MARKET
7
SUSTAINABILITY AND REGULATORY LANDSCAPE
7.1
REGIONAL REGULATIONS AND COMPLIANCE
7.1.1
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.2
EPIDEMIOLOGY OF DIABETES, BY KEY COUNTRIES
7.3
SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES
7.4
CERTIFICATIONS, LABELING, ECO-STANDARDS
8
CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.1
DECISION-MAKING PROCESS
8.2
BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
8.3
ADOPTION BARRIERS & INTERNAL CHALLENGES
8.4
UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
9
ASIA PACIFIC BLOOD GLUCOSE MONITORING DEVICES MARKET DATA, BY PRODUCT (MARKET SIZE & FORECAST TO 2030 – IN VALUE, USD MILLION & VOLUME UNITS)
9.2
SELF-MONITORING BLOOD GLUCOSE SYSTEMS
9.2.3
LANCETS & LANCING DEVICES
9.3
CONTINUOUS GLUCOSE MONITORING SYSTEMS
9.3.3
TRANSMITTERS & RECEIVERS
9.4
PROFESSIONAL POINT OF CARE DEVICES
9.5
NON-INVASIVE PRODUCTS
10
ASIA PACIFIC BLOOD GLUCOSE MONITORING DEVICES MARKET DATA, BY TEST SITE (MARKET SIZE & FORECAST TO 2030 – IN VALUE, USD MILLION & VOLUME UNITS)
10.4
ALTERNATES SITES (SUCH AS ABDOMEN, THIGH, CALF, PALM, ETC.)
11
ASIA PACIFIC BLOOD GLUCOSE MONITORING DEVICES MARKET DATA, BY APPLICATION (MARKET SIZE & FORECAST TO 2030 – IN VALUE, USD MILLION & VOLUME UNITS)
11.3
HEALTH AND WELLNESS MONITORING
11.4
OTHER APPLICATIONS (REMOTE MONITORING, GESTATIONAL DIABETES)
12
ASIA PACIFIC BLOOD GLUCOSE MONITORING DEVICES MARKET DATA, BY END USER (MARKET SIZE & FORECAST TO 2030 – IN VALUE, USD MILLION & VOLUME UNITS)
12.5
OTHER END USERS (AMBULATORY CARE CENTERS, REHABILITATION CENTERS, AND OLD AGE HOMES)
13
ASIA PACIFIC BLOOD GLUCOSE MONITORING DEVICES MARKET DATA, BY COUNTRY (MARKET SIZE & FORECAST TO 2030 – IN VALUE, USD MILLION & VOLUME UNITS)
13.7
REST OF ASIA PACIFIC
14.2
KEY PLAYER COMPETITIVE STRATEGIES/RIGHT TO WIN
14.3
REVENUE ANALYSIS, 2020-2024
14.4
MARKET SHARE ANALYSIS,
14.5
COMPANY EVALUATION MATRIX: KEY PLAYERS,
14.5.5
COMPANY FOOTPRINT: KEY PLAYERS,
14.5.5.1
COMPANY FOOTPRINT
14.5.5.2
REGION FOOTPRINT
14.5.5.3
PRODUCT FOOTPRINT
14.5.5.4
TEST SITE FOOTPRINT
14.5.5.5
APPLICATION FOOTPRINT
14.5.5.6
END USER FOOTPRINT
15.6
COMPANY EVALUATION MATRIX: STARTUPS/SMES,
15.6.1
PROGRESSIVE COMPANIES
15.6.2
RESPONSIVE COMPANIES
15.6.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES,
15.6.5.1
DETAILED LIST OF KEY STARTUPS/SMES
15.6.5.2
COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
15.7
COMPETITIVE SCENARIO
15.7.4
OTHER DEVELOPMENTS
15.8
BRAND/PRODUCT COMPARISON
15.8.1
ABBOTT LABORATORIES (FREESTYLE)
15.8.2
DEXCOM, INC. (G6 & G7 CGM)
15.8.3
MEDTRONIC (GUARDIAN)
15.8.4
F. HOFFMANN-LA ROCHE AG (ACCU-CHEK)
15.9
COMPANY VALUATION AND FINANCIAL METRICS
(BUSINESS OVERVIEW, PRODUCTS OFFERED, INDUSTRY-SPECIFIC DEVELOPMENTS FOR 2022-2025)
16.1.1
ABBOTT LABORATORIES
16.1.4
F. HOFFMANN-LA ROCHE LTD
16.1.8
ASCENSIA DIABETES CARE HOLDINGS AG
16.1.9
B. BRAUN SE B. BRAUN SE
16.1.11
SD BIOSENSOR, INC
16.1.13
TERUMO CORPORATION
16.1.14
LIFESCAN IP HOLDINGS, LLC
16.1.15
MEDICAL TECHNOLOGY AND DEVICES S.P.A.
17.1.1.1
KEY DATA FROM SECONDARY SOURCES
17.1.2.1
KEY DATA FROM PRIMARY SOURCES
17.1.2.2
KEY PRIMARY PARTICIPANTS
17.1.2.3
BREAKDOWN OF PRIMARY INTERVIEWS
17.1.2.4
KEY INDUSTRY INSIGHTS
17.2
MARKET SIZE ESTIMATION
17.2.1
BOTTOM-UP APPROACH
17.2.3
BASE NUMBER CALCULATION
17.3
MARKET FORECAST APPROACH
17.6
RESEARCH ASSUMPTIONS
17.7
RESEARCH LIMITATIONS AND RISK ASSESSMENT
18.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
18.3
CUSTOMIZATION OPTIONS
Growth opportunities and latent adjacency in Asia Pacific Blood Glucose Monitoring Devices Market